The phase 4 PADMA study showed meaningful improvements in TFF and PFS in patients with high-risk HR-positive/HER2-negative metastatic breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback